Back to results
US 2021/0230252 A1Published application
Tgf-beta receptor type ii variants and uses thereof
AssigneeAcceleron Pharma Inc.
InventorsRavindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.
Claims11
1-16. (canceled)
A method of identifying functional mutants of a TβRII polypeptide, comprising:
- a. producing a combinatorial library of genes encoding variant polypeptides;
- and
- b. evaluating the ability of each variant polypeptide to bind to Transforming Growth Factor β1 and Transforming Growth Factor β3.
Dependencies are inferred from the claim text.